Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03337789
Other study ID # PSE
Secondary ID
Status Completed
Phase N/A
First received November 6, 2017
Last updated January 20, 2018
Start date November 7, 2016
Est. completion date December 31, 2017

Study information

Verified date January 2018
Source Ewha Womans University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate the efficacy and safety of Polygonatum sibiricum for sleep quality improvement.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 31, 2017
Est. primary completion date December 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Male and female volunteers who are between the ages of 20 and 65

- Experienced any of the following sleep problems, at least more than once a week for more than 2 months: 1) difficulty in falling asleep or staying asleep; 2) waking up at dusk and not being able to fall asleep again; 3) not feeling refreshed even after getting some sleep.

Exclusion Criteria:

- Diagnosed with insomnia assessed with a structured interview and sleep scale measurements

- Possibility of drug-induced sleep disorders due to current intake of medication (i.e., corticosteroid, statin, etc)

- Had taken sleeping pills (i.e., zolpidem, benzodiazepine) during the past 2 months

- Diagnosed with any major medical or neurological disorders assessed during medical history taking, physical examination or experimental tests.

- Diagnosed with any axis 1 psychiatric disorders (depressive disorder, bipolar disorder, alcohol dependence, schizophrenia) evaluated with a structured instrument

- A history of traumatic brain injury with loss of consciousness, or any contraindications to MRI (i.e., claustrophobia, metallic foreign devices in body)

- Had taken psychotropic drugs within the past 3 months before study participation

- Allergic to polygonatum sibiricum or experienced side effects after consumption of any product containing polygonatum sibiricum

- Participated in another clinical trial or took other medications during the period that may influence the results of this clinical trial

- Currently taking contraceptive pills

- Planning for pregnancy during the period of study participation, currently pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms

  • Healthy Adults With Subjective Sleep Complaints

Intervention

Dietary Supplement:
Polygonatum sibiricum
Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
Placebo
Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks

Locations

Country Name City State
Korea, Republic of Ewha Womans University Seoul

Sponsors (1)

Lead Sponsor Collaborator
Ewha Womans University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline subjective sleep quality at 4 weeks assessed by Pittsburgh Sleep Quality Index Baseline and week 4
Primary Chagne from baseline physical activity at 4 weeks assessed by actigraph Baseline and week 4
Primary Change from baseline objective sleep quality at 4 weeks assessed by polysomnography Baseline and week 4
Secondary Change from baseline cognitive functions at 4 weeks assessed by the neuropsychological test battery Baseline and week 4
Secondary Change from baseline depressive symptom levels at 4 weeks assessed by the Hamilton Depression Rating Scale Scale name: Hamilton Depression Rating Scale
/ Range of total score: 0 - 52 (Higher scores represent more severe depressive symptoms.)
Baseline and week 4
Secondary Change from baseline anxiety symptom levels at 4 weeks assessed by the Hamilton Anxiety Rating Scale Scale name: Hamilton Anxiety Rating Scale
/ Range of total score: 0 - 56 (Higher scores represent more severe anxiety symptoms.)
Baseline and week 4
Secondary Change from baseline brain structure, function, and metabolism at 4 weeks assessed by computational analysis of magnetic resonance imaging data Baseline and week 4